Clinical trials
Retinal Vein Occlusion clinical trials
Below are recruiting retinal vein occlusion clinical trials, each written for real people, not researchers. We’re tracking 12 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07708142RecruitingPhase 3
Testing a new injection for swelling after retinal vein blockage
This trial tests a new medicine called SMO1 for people with vision loss and swelling in the eye caused by a blocked vein in the retina. It involves regular eye injections to see if the medicine can reduce swelling and improve vision.
Seoul, Gangdong-guAges 19 years+ - NCT04505618Recruiting
Eye scan study using special imaging for blood-vessel disease
This study uses a detailed eye scan (optical coherence tomography angiography) to look at how blood vessels in the retina are affected. It may help researchers better understand retinal vascular diseases, though some people will be excluded for safety or image-quality reasons.
Baltimore, MarylandAges 18–99 - NCT07133438RecruitingPhase 4
Vitamin B12 with eye injections for blocked retinal vein
This trial tests if adding mecobalamin (a form of vitamin B12) to standard anti-VEGF eye injections helps people with vision loss caused by a blocked vein in the retina. You must have swelling in the back of the eye and have had no prior treatments for this condition.
ChongqingAges 18–80 - NCT07259928RecruitingPhase 2
Testing ANXV for diabetic retinopathy or retinal vein occlusion
This trial tests a new drug called ANXV (Annexin A5) to see if it is safe and can help people with diabetic retinopathy or a recent retinal vein occlusion. The goal is to reduce eye damage and improve vision.
LondonAges 18 years+ - NCT01496625Recruiting
Biobank study for retinal diseases and comparison samples
This study collects and stores blood and eye-related medical information to help researchers better understand retinal diseases, including age-related macular degeneration and diabetic retinopathy. Your samples may also be used to compare people with retinal disease to people without it.
Bethesda, MarylandAges 2–120 - NCT03680794Recruiting
Testing a blood and eye-fluid marker in retinal disease
This study looks at a specific lab marker (sCD160) in blood and eye fluids to see how it relates to poor blood flow in the retina. You may be asked for samples taken during eye surgery to help doctors understand the disease better.
ReimsAges 18 years+ - NCT04008121RecruitingEarly Phase 1
Testing an eye imaging drug during retinal blood-vessel photos
This early safety study tests how well and how safely an investigational dye (MB-102) works during a special eye imaging test of retinal and choroidal blood vessels. It compares it to the commonly used fluorescein dye and may help doctors refine future eye imaging approaches.
Ann Arbor, MichiganAges 18 years+ - NCT07002372Recruiting
Watching a video before your first eye injection
This study tests whether watching a short video before your first eye injection helps you feel more at ease. It is for people who have never had this injection before.
Hangzhou, ZhejiangAges 18 years+ - NCT07205887RecruitingPhase 2
Study of EYE103 for wet AMD or macular edema after BRVO
This trial tests an investigational drug called EYE103 injected into the eye to treat two conditions: wet age-related macular degeneration (AMD) or macular edema following a branch retinal vein occlusion (BRVO). It looks at how safe and effective the drug is for people who have not had treatment before or have not responded well to previous treatments.
Scottsdale, ArizonaAges 18 years+ - NCT07308639Recruiting
Eye disease health data study in Germany
This study looks at health records in Germany to understand how many people have certain eye conditions like age-related macular degeneration, diabetic macular edema, or retinal vein occlusion. It also tests new ways to use this information for research.
LeverkusenAges 18 years+ - NCT07456826Enrolling by invitationPhase 4
Comparing two eye numbing gels for shots
This trial tests a new eye-numbing gel against the standard numbing method to see which works better for patients getting regular anti-VEGF injections in the eye.
Tyler, TexasAges 18 years+ - NCT07550777Recruiting
Heart Health and Eye Injections Study
This study looks at how repeated eye injections of a drug called bevacizumab affect chemicals in your blood that relate to heart health and inflammation. Researchers want to understand if these eye injections might impact your cardiovascular risk.
Erzurum, ErzurumAges 50–80
Hear when a new Retinal Vein Occlusion trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for retinal vein occlusion?
- Yes. Clin2 currently lists 12 recruiting retinal vein occlusion studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a retinal vein occlusion trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a retinal vein occlusion trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.